A recent article by journalist Patrick Adams highlights the need for greater use and awareness of the CrAg LFA as a diagnostic, and the critical importance of implementing national screening programs for patients with low CD4 counts.
“Global health experts believe (the CrAg LFA) could be key to stopping one of the planet’s biggest killers: cryptococcal meningitis”
IMMY CrAg® LFA
The IMMY CrAg LFA (Cryptococcal Antigen Lateral Flow Assay) is the first and only immunochromatographic dipstick assay for the qualitative and semiquanitative detection of cryptococcal antigen. This lateral flow assay is revolutionizing cryptococcal antigen testing, by delivering analytical sensitivity that is up to 200x more sensitive than other commercial assays. The CrAg LFA is empowering health care providers in all clinical settings with rapid, reliable, and robust diagnostic results.
Unlike other cryptococcal antigen diagnostics on the market, the CrAg LFA has excellent sensitivity across all four serotypes of Cryptococcus, including C. gattii.
The 2 year shelf life and room temperature storage ensures no reagents are wasted. Also, the moderate complexity CLIA rating allows for cryptococcal antigen testing to be easily offered on all laboratory shifts, on a STAT basis, and as a Point-of-Care assay.
Key Advantages of the CrAg LFA:
- 10 minute test time | 1 minute tech time
- No specimen Pretreatment
- No Boiling (CSF)
- No Pronase™/Protease™ (serum)
- 2 year shelf life | Room temperature storage | Condensed Packaging
- Internal Control line eliminates costly external control requirement
- Qualitative and semi-quantitative results
- As easy as a home pregnancy test
- Only Product FDA-cleared for both C. neoformans and C. gattii
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
